Form 4 for FBLG FibroBiologics, Inc.

Accepted 2026-09-15 19:26:30 ET · period of report 2026-09-15 · accession 0001493152-26-042794 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2026-09-15 19:26	2026-09-15	FBLG	Khoja Hamid	CSO	A - Grant	$1.68	+298.5K	301.6K	+9,746%	+$500.0K
D	2026-09-15 19:26	2026-09-15	FBLG	Khoja Hamid	CSO	A - Grant	—	+298.5K	298.5K	New	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-09-15	A	A	298,508	$1.68	301,571	D	—	—	(F1) On September 15, 2026, the reporting person entered into a securities purchase agreement with FibroBiologics, Inc. (the "Company") to purchase 298,508 shares of the Company's common stock, par value $0.00001 per share (the "Common Stock"), and accompanying warrants to purchase up to 298,508 shares of Common Stock (the "Warrants"), in a private placement (the "Offering"). (F2) Each share of Common Stock and accompanying Warrant were issued at a combined purchase price of $1.675.
2	Derivative	Warrant (Right to Buy)	2026-09-15	A	A	298,508	—	298,508	D	$1.55 · — to 2031-09-15	298,508 Common Stock	(F1) On September 15, 2026, the reporting person entered into a securities purchase agreement with FibroBiologics, Inc. (the "Company") to purchase 298,508 shares of the Company's common stock, par value $0.00001 per share (the "Common Stock"), and accompanying warrants to purchase up to 298,508 shares of Common Stock (the "Warrants"), in a private placement (the "Offering"). (F2) Each share of Common Stock and accompanying Warrant were issued at a combined purchase price of $1.675. (F3) The warrants are exercisable at any time until they expire.